Exact Mass: 453.2171
Exact Mass Matches: 453.2171
Found 88 metabolites which its exact mass value is equals to given mass value 453.2171
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
20-Oxo-leukotriene E4
20-oxo-leukotriene E4 is a metabolite through lipid oxidation of Leukotriene E4 (LTE4).Leukotriene E4 (LTE4) is a cysteinyl leukotriene. Cysteinyl leukotrienes (CysLTs) are a family of potent inflammatory mediators that appear to contribute to the pathophysiologic features of allergic rhinitis. Nasal blockage induced by CysLTs is mainly due to dilatation of nasal blood vessels, which can be induced by the nitric oxide produced through CysLT1 receptor activation. LTE4, activate contractile and inflammatory processes via specific interaction with putative seven transmembrane-spanning receptors that couple to G proteins and subsequent intracellular signaling pathways. LTE4 is metabolized from leukotriene C4 in a reaction catalyzed by gamma-glutamyl transpeptidase and a particulate dipeptidase from kidney. (PMID: 12607939, 12432945, 6311078). Leukotrienes are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent, able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis, through receptor-mediated G-protein linked signalling pathways. 20-oxo-leukotriene E4 is a metabolite through lipid oxidation of Leukotriene E4 (LTE4).Leukotriene E4 (LTE4) is a cysteinyl leukotriene. Cysteinyl leukotrienes (CysLTs) are a family of potent inflammatory mediators that appear to contribute to the pathophysiologic features of allergic rhinitis. Nasal blockage induced by CysLTs is mainly due to dilatation of nasal blood vessels, which can be induced by the nitric oxide produced through CysLT1 receptor activation. LTE4, activate contractile and inflammatory processes via specific interaction with putative seven transmembrane-spanning receptors that couple to G proteins and subsequent intracellular signaling pathways. LTE4 is metabolized from leukotriene C4 in a reaction catalyzed by gamma-glutamyl transpeptidase and a particulate dipeptidase from kidney. (PMID: 12607939, 12432945, 6311078)
2-[[N-Methyl-N-[5-guanidino-2-[(2-amino-3-methylbutyryl)amino]pentanoyl]hydrazino]phosphonyl]-2-hydroxyacetic acid methyl ester
Gly Lys Ser Tyr
Gly Lys Tyr Ser
Gly Ser Lys Tyr
Gly Ser Tyr Lys
Gly Tyr Lys Ser
Gly Tyr Ser Lys
Lys Gly Ser Tyr
Lys Gly Tyr Ser
Lys Ser Gly Tyr
Lys Ser Tyr Gly
Lys Tyr Gly Ser
Lys Tyr Ser Gly
Ser Gly Lys Tyr
Ser Gly Tyr Lys
Ser Lys Gly Tyr
Ser Lys Tyr Gly
Ser Tyr Gly Lys
Ser Tyr Lys Gly
Tyr Gly Lys Ser
Tyr Gly Ser Lys
Tyr Lys Gly Ser
Tyr Lys Ser Gly
Tyr Ser Gly Lys
Tyr Ser Lys Gly
20-Oxo-leukotriene E4
(S)-2-Fmoc-Amino-Heptanedioic Acid 7-Tert-Butyl Ester
SB590885
SB-590885 is a potent?B-Raf?inhibitor with?Ki?of 0.16 nM, and has 11-fold greater selectivity for B-Raf over c-Raf, without inhibition to other human kinases.
1H-1-Benzazepine-5-acetamide, 1-(2-chloro-4-(1-pyrrolidinyl)benzoyl)-2,3,4,5-tetrahydro-N-(1-methylethyl)-, (R)-
N-{1-[(1-carbamoylcyclopropyl)methyl]piperidin-4-yl}-N-cyclopropyl-4-[(1S)-2,2,2-trifluoro-1-hydroxy-1-methylethyl]benzamide
(20s)-19,20,22,23-Tetrahydro-19-oxo-5h,21h-18,20-ethano-12,14-etheno-6,10-methenobenz[d]imidazo[4,3-l][1,6,9,13]oxatriazacyclonoadecosine-9-carbonitrile
(5S,6R,7E,9E,11Z,14Z)-6-{[(2R)-2-amino-2-carboxyethyl]sulfanyl}-5-hydroxy-20-oxoicosa-7,9,11,14-tetraenoic acid
(3R,3aS,7R,7aS)-3-[3-(4-acetylphenyl)-4-fluorophenyl]-7-methyl-2-(phenylmethyl)-3a,6,7,7a-tetrahydro-3H-isoindol-1-one
(3R,3aR,7aR)-3-[4-(4-acetylphenyl)-2-fluorophenyl]-7a-methyl-2-(phenylmethyl)-3,3a,6,7-tetrahydroisoindol-1-one
(5aS,7S,8aR,9aS)-7,7,8,8-tetramethyl-5a-nitrospiro[1,2,3,5,6,8a,9,9a-octahydrocyclopenta[f]indolizine-7,3-1,8-dihydropyrano[2,3-g]indole]-2,9-dione
(E)-3,7,11,15-tetramethylhexadec-2-en-1-yl diphosphate(3-)
N-[2-methyl-4-oxo-3-(phenylmethyl)-7-(1-piperidinyl)-6-quinazolinyl]-3-pyridinecarboxamide
3-butan-2-yl-1-[(6,7-dimethoxy-2-oxo-1H-quinolin-3-yl)methyl]-1-(2-phenylethyl)thiourea
1-(4-amino-1,2,5-oxadiazol-3-yl)-5-(azepan-1-ylmethyl)-N-[(E)-(2-ethoxyphenyl)methylidene]-1H-1,2,3-triazole-4-carbohydrazide
1-(4-Amino-1,2,5-oxadiazol-3-YL)-N-[(E)-(2-ethoxyphenyl)methylidene]-5-[(4-methylpiperidin-1-YL)methyl]-1H-1,2,3-triazole-4-carbohydrazide
3-(3,4-dimethoxyphenyl)-2-methyl-N-[2-(4-morpholinyl)ethyl]-1-oxo-3,4-dihydroisoquinoline-4-carboxamide
1-(4-Amino-1,2,5-oxadiazol-3-YL)-N-[(E)-(4-ethoxyphenyl)methylidene]-5-[(4-methylpiperidin-1-YL)methyl]-1H-1,2,3-triazole-4-carbohydrazide
methyl (1S,9R,10R,11R)-5-[3-(dimethylcarbamoyl)phenyl]-10-(hydroxymethyl)-6-oxo-12-propyl-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxylate
methyl (1R,9S,10S,11S)-5-[3-(dimethylcarbamoyl)phenyl]-10-(hydroxymethyl)-6-oxo-12-propyl-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxylate
(3aR,4R,9bS)-8-(1-cyclohexenyl)-N-(2,5-difluorophenyl)-4-(hydroxymethyl)-5-methyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinoline-1-carboxamide
[(1S)-2-(cyclopropylmethyl)-1-[(2,5-difluorophenyl)methyl]-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]methanol
5-aminopentyl 3-O-(2-O-acetyl-6-deoxy-alpha-L-talopyranosyl)-beta-D-glucopyranoside
2-amino-3-[hydroxy-[2-hydroxy-3-[(Z)-tridec-9-enoyl]oxypropoxy]phosphoryl]oxypropanoic acid
20-oxoleukotriene E4
A leukotriene that is leukotriene E4 in which the terminal methyl grop has been oxidised to the corresponding aldehyde